Question explored with the scientific record
Continuing hrt after 65
The short version: continuing HRT past 65 shifts the risk profile from symptom relief toward cancer, clot, and cardiovascular harm, and the evidence does not support it for most women.
The evidence that matters comes from the WHI and HERS trials, which studied women averaging 63–67 years on oral conjugated equine estrogen plus medroxyprogesterone acetate [24]. Those trials found an 81% increase in heart attack in the first year, increased stroke, breast cancer, and venous thromboembolism, with no mortality benefit [24]. The Cochrane review of 40,000 women found 5 extra VTE cases per 1000 users [1]. The E3N cohort of 54,548 women found a 40% higher breast cancer risk with synthetic progestins (RR 1.4, CI 1.2–1.7) [7]. A UK prospective study of 17,497 women found a 21% increase in all CNS tumors with estrogen-only therapy [3].
The route matters. Oral estrogen raises C-reactive protein (2.75 vs 1.27 mg/L for transdermal) [15], worsens insulin resistance in metabolic syndrome [16], and increases liver enzyme fluctuations [19]. Transdermal estrogen avoids the first-pass liver effect and lowers inflammatory markers [25], but the long-term safety data for transdermal use past 65 is thin. The KEEPS trial studied women with mean age 52.7, not 65+ [24]. The ELITE trial showed benefit only when started within 6 years of menopause [24]. No trial has randomized women over 65 to transdermal versus oral and followed them for hard outcomes.
| Outcome | Oral CEE+MPA (WHI, per 1000 users) | Transdermal estradiol (limited data) |
|---|---|---|
| Heart attack in first year | 81% increase [24] | No trial in this age group |
| VTE | 5 extra cases [1] | Lower risk assumed, no trial |
| Breast cancer | RR 1.4 with synthetic progestins [7] | No long-term data past 65 |
| CNS tumors | RR 1.21 for all tumors [3] | Not studied |
My call: continuing HRT past 65 is not supported by the evidence for most women. The risks of breast cancer, VTE, stroke, and cardiovascular events outweigh the symptom benefits, which are smaller at this age. Transdermal estradiol with micronized progesterone may be safer, but the evidence does not exist for this age group. Confidence: high for oral combined therapy, low for transdermal because the key studies were never done.
Sources examined 25
-
Hormone therapy and cardiovascular disease – are we back to the beginning?
This paper reviews the updated Cochrane Review on menopause hormone therapy (MHT) and its effects on cardiovascular disease, highlighting the differing impacts based on the timing of therapy initiation relative to menopause.
DOI: 10.3109/13697137.2015.1057958 -
Relation between pelvic organ prolapse and menopausal hormone therapy: nationwide cohort study
This nationwide cohort study investigates the relationship between menopausal hormone therapy (MHT) and the risk of pelvic organ prolapse (POP), finding that tibolone and combined estrogen plus progestin are associated with a reduced risk of POP compared to non-MHT.
DOI: 10.5468/ogs.24071 -
Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta‐analysis
This study investigates the association between menopausal hormone therapy (HT) and the risk of central nervous system (CNS) tumors, revealing a significant increased risk for all CNS tumors and specific types like glioma and meningioma in users of estrogen-only HT based on a la…
DOI: 10.1002/ijc.29274 -
Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition
In a large European prospective cohort of postmenopausal women (EPIC), menopausal hormone therapy use was not significantly associated with colorectal cancer risk, with no clear differences by HT type, recency, duration, route of administration, or hormonal constituents.
DOI: 10.1002/ijc.25504 -
Menopausal hormone therapy and sleep-disordered breathing: evidence for a healthy user bias
An observational study of the Sleep in Midlife Women Study within the Wisconsin Sleep Cohort investigates whether menopausal hormone therapy is associated with sleep-disordered breathing, testing for a healthy user bias by comparing associations before and after July 2002 (WHI p…
DOI: 10.1016/j.annepidem.2015.07.004 -
Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
A PEPI trial substudy showing that, among postmenopausal women treated with estrogen plus progestin, changes in serum estrone after 1 year strongly predict increases in mammographic density (driven by increased dense tissue), whereas estrone changes do not predict density change…
DOI: 10.1200/jco.2004.03.120 -
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort
This study investigates the association between different types of hormone replacement therapy (HRT) and breast cancer risk in a cohort of 54,548 postmenopausal women, finding that HRT users have a higher risk compared to non-users, particularly with synthetic progestins.
DOI: 10.1002/ijc.20710 -
Breast cancer risk associated with different HRT formulations: a register-based case-control study
Lifetime hormone replacement therapy use is associated with a small increase in breast cancer risk among German women, with little evidence that risk differs substantially by formulation, although residual confounding and bias limit causal interpretation.
DOI: 10.1186/1472-6874-6-13 -
A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers
A randomized 2-by-2 factorial trial in 226 recently postmenopausal women compared oral conjugated equine estrogen (CEE) versus transdermal estradiol (E2) with sequential medroxyprogesterone acetate, and fenretinide versus placebo, assessing changes in key breast cancer risk biom…
DOI: 10.1158/1078-0432.ccr-04-0087 -
Endocrine care of transpeople part II . A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen
This 2015 clinical review synthesizes cross‑sex hormonal therapy regimens, outcomes, and adverse effects in transwomen, highlighting safer estrogen formulations, monitoring needs, and long‑term health considerations to improve well‑being while mitigating thromboembolism, cardiov…
DOI: 10.1111/cen.12754 -
Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT
This study evaluates the quality of life in postmenopausal women undergoing hormone replacement therapy with oral conjugated equine estrogen or transdermal estradiol, alongside fenretinide or placebo, revealing that both hormone therapies significantly alleviate menopausal sympt…
DOI: 10.1016/j.maturitas.2006.01.005 -
Breast tenderness after initiation of conjugated equine estrogens and mammographic density change
This study investigates the association between new-onset breast tenderness and changes in mammographic density following the initiation of conjugated equine estrogens (CEE) in postmenopausal women, revealing that CEE combined with medroxyprogesterone acetate (MPA) significantly…
DOI: 10.1007/s10549-011-1803-9 -
Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy
A randomized 1-year clinical trial in 100 postmenopausal women comparing low-dose (0.3 mg) versus standard-dose (0.625 mg) conjugated equine estrogen for hormone replacement therapy; both doses provided similar relief of vasomotor/genitourinary/psychological symptoms, but the hi…
DOI: 10.5005/jp-journals-10032-1011 -
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
This study evaluates the efficacy and safety of oral and vaginal estrogens in preventing recurrent urinary tract infections (RUTI) in postmenopausal women, finding that vaginal estrogens may reduce UTI occurrences while oral estrogens do not show significant benefits.
DOI: 10.1002/14651858.CD005131.pub2 -
Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen
This study investigates the effects of oral versus transdermal estrogen hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women, finding that oral estrogen significantly increases these levels while transdermal estradiol decreases them.
DOI: 10.1016/s0002-9343(02)01209-3 -
A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome
This study compares the effects of oral versus transdermal estrogen therapy on insulin resistance and adipocytokine levels in obese postmenopausal women with metabolic syndrome, finding that oral estrogen worsens insulin resistance while transdermal estrogen has minimal effects.
DOI: 10.1016/j.fertnstert.2006.04.043 -
The Effects of a "Low-Estrogen" Oral Contraceptive on Carbohydrate Metabolism During Six Months of Treatment: A Preliminary Report of Blood Glucose and Plasma Insulin Values
This study investigates the effects of a low-estrogen oral contraceptive on carbohydrate metabolism in seven women over six months, finding a significant reduction in one-hour blood glucose levels without notable changes in plasma insulin or weight.
DOI: 10.1016/s0015-0282(16)42747-0 -
Differences in associations of follicle-stimulating hormone with lipid profiles according to oral and transdermal hormone replacement therapy in Japanese women during the menopausal transition
This study investigates how follicle-stimulating hormone (FSH) and luteinizing hormone (LH) relate to lipid profiles in Japanese peri- and postmenopausal women and how changes in FSH during hormone replacement therapy (HRT) with oral versus transdermal estrogen influence LDL-C, …
DOI: 10.2152/jmi.72.290 -
Longitudinal Study of Liver Enzymes and Serum Levels of Estradiol During Hormonal Replacement Therapy in Patients With Turner Syndrome
A longitudinal clinical study in Turner syndrome patients evaluating the hepatic effects of estrogen replacement therapy, comparing induced puberty with oral estrogen (conjugated equine estrogens followed by 17β-estradiol) to spontaneous puberty without hormone replacement, find…
DOI: 10.1097/01.ten.0000257435.71801.c1 -
A prospective study of oral estrogen versus transdermal estrogen (gel) for hormone replacement frozen embryo transfer cycles
This prospective cohort study compared oral estradiol valerate tablets with transdermal estradiol gel for endometrial preparation in hormone replacement frozen embryo transfer (HR-FET) cycles (n=294), finding no meaningful differences in endometrial thickness, implantation rate,…
DOI: 10.1080/09513590.2020.1793941 -
Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women
This study compares the effects of tibolone, transdermal estrogen, and oral estrogen/progestogen therapy on bone mineral density in postmenopausal women, finding that tibolone significantly increases spine BMD over three years compared to the other treatments.
DOI: 10.3109/09513599609023606 -
Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement
A quasi-randomized, single-center study in perimenopausal women testing a very low estrogen oral contraceptive (20 pg ethinyl estradiol + 150 μg desogestrel) for climacteric relief, with accompanying hormonal, lipid, and endometrial assessments over six months, showing symptom i…
DOI: 10.1016/0378-5122(94)90047-7 -
The Haemolytic Uraemic Syndrome and Oral Contraceptives
This case report describes a young woman who developed haemolytic uraemic syndrome following a change to a higher estrogen oral contraceptive, highlighting the potential link between estrogen levels and the syndrome's onset.
DOI: 10.1111/j.1445-5994.1976.tb04000.x -
Menopausal Hormone Therapy: a Comprehensive Review
Comprehensive narrative review summarizing historical and current evidence on menopausal hormone therapy (MHT) and cardiovascular risk in women, including WHI/HERS trials, the timing window hypothesis, newer low-dose/alternative routes, and current risk-benefit guidelines for cl…
DOI: 10.1007/s11883-020-00854-8 -
Effects of Transdermal Estrogen Replacement Therapy on Cardiovascular Risk Factors
This study investigates the effects of transdermal estrogen replacement therapy on cardiovascular risk factors in postmenopausal women, highlighting its advantages over oral estrogen in terms of lipid metabolism and inflammatory markers.
DOI: 10.2165/00024677-200605010-00005